Aldeyra Therapeutics Inc TRANQUILITY-2 Top-Line Data Results Call Transcript
Good morning, and welcome to the Aldeyra Therapeutics conference call. My name is Bailey, and I'll be the moderator for today's call. (Operator Instructions)
I would now like to hand the conference over to Bruce Greenberg, Vice President of Finance, Interim Chief Financial Officer and Treasurer. Thank you. Sir, please go ahead.
Thank you, and good morning, everyone. With me is Dr. Todd Brady, President and Chief Executive Officer of Aldeyra. This morning, we issued a press release reporting top line results for the Phase III TRANQUILITY-2 clinical trial of our investigational new drug candidate, reproxalap, in patients with dry eye disease. A copy of the press release is available on the Investors & Media section of our website, www.aldeyra.com. The press release should be read and considered in conjunction with the slides presented and prepared comments made on today's call.
Please turn
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |